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Highlights 
 A high number of patients with JME and JAE in remission withdrew from AEDs. 
 All patients with JAE and 80% of patients with JME relapsed after AED withdrawal. 
 25% of patients with JAE continuing on AEDs relapsed. 
 36% of patients with JME continuing on AEDs relapsed. 
 
 
Abstract 
Purpose 
Conventional teaching is that juvenile myoclonic epilepsy (JME) and juvenile absence epilepsy 
(JAE) require lifelong antiepileptic drug (AED) treatment.  We therefore wanted to determine 
how many patients attending our epilepsy service with JAE or JME went into 2 year remission, 
and then relapsed, both off and on AEDs. 
 
Method 
This was a retrospective case-notes review. Patients with JAE and JME were systematically 
ascertained from clinic lists and databases at one teaching hospital. Data was extracted 
systematically. Simple descriptive statistics were used. 
 
Results 
JAE: 14/36 (39%) were seizure free on AEDs for at least 2 years.  Of the 6 (43%) attempting 
AED withdrawal, all (100%) relapsed, compared with only 25% of those who did not withdraw 
AEDs. Only 2/5 who relapsed and restarted AEDs regained remission. AC
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JME: 32/145 (22%) were seizure free on AEDs for at least 2 years.  Of the 10 (31%) attempting 
AED withdrawal, 8 (80%) relapsed, compared with only 36% of those who did not withdraw 
AEDs.  Only 2/8 who relapsed and restarted AEDs regained remission.   
 
Conclusion 
Remission rates for JAE and JME was lower than expected.  Higher proportions of seizure free 
patients underwent physician-supervised withdrawal than anticipated.  Relapse rates off AEDs 
were similar for JAE and JME, and at least twice as high as for those remaining on AEDs, and a 
further remission was not invariable on restarting AEDs.  Our experience, comparing relapse in 
those withdrawing to those staying on AEDs will help in discussions with patients keen to try 
AED withdrawal. 
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Introduction 
The objective of this clinical audit was to assess current practice and experience of remission, 
antiepileptic drug (AED) withdrawal, and relapse in young people and adults with Juvenile 
Absence Epilepsy (JAE), and Juvenile Myoclonic Epilepsy (JME). 
 
Background 
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JAE and JME are Genetic Generalised Epilepsy syndromes (GGE)[1], previously known as 
Idiopathic Generalised Epilepsy syndromes (IGE)[2]. Epilepsies in this group occur principally 
in patients with otherwise normal brain structure and function. They are generally of shared 
complex inheritance with reduced penetrance, sharing susceptibility alleles at more than one 
locus[3]. There is some controversy over what criteria should be used to diagnose individuals as 
having JAE or JME[2,4,5]. Furthermore, as well as sharing clinical features e.g. age of onset, 
lack of associated encephalopathy, EEG features, there is overlap in the seizures expressed. In 
JAE all have typical absence seizures (AS) and most have generalised tonic-clonic seizures 
(GTCS). In JME awakening myoclonus is the hallmark, but most patients also have GTCS and 
many have AS.  
 
The phenotypic similarities and overlaps in GGEs, especially juvenile (adolescent) onset GGEs, 
are reflected in segregation and twin studies[6-8]. So given the clinical, EEG, and underlying 
genetic commonalities, we might expect JME and JAE to share treatment responsiveness and 
prognosis. Indeed it has been argued that they could be regarded as one type of epilepsy[9].   
 
Rates of JME remission previously reported 
There is a range of remission rates reported for JME.  A retrospective review of 50 patients with 
JME on treatment found 86% were seizure free for at least one year[10]. A similarly high rate of 
remission was reported in a cohort of 66 patients followed up prospectively for 5 years, with 
88% becoming seizure free for at least three years[4]. A questionnaire study of 43 JME patients 
found 79% had experienced no GTCS in the previous year, but a more modest 41% were entirely 
seizure free[11]. A clinic based study of 13 patients showed only 38% were seizure free[12]. A 
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large prospective study of 257 JME patients reported remission in 58% of the 186 patients 
considered to have classical JME, but a much lower rate of remission of 7% in the subtype which 
had evolved from an earlier CAE type epilepsy[13]. Two additional retrospective studies of 200 
patients[14]  and 55 patients[15], found similar rates of seizure freedom, 75% and 73% 
respectively. 78% of a cohort of 24 patients followed up for mean of 25 years achieved seizure 
freedom at some point[5]. A recent study used both review of records and interviews of 31 
patients after a minimum follow-up of 25 years and reported that 67% were seizure-free on 
treatment; no correlation was found in this study between seizure freedom and prior history of 
CAE[16]. Another study using interviews of 42 patients after 20 years follow-up found 21 were 
in remission of at least 5 years[17]. A further retrospective cohort study of 66 patients with 
follow-up of between 20-69 years reported that 59% were seizure-free for over 5 years[18]. A 
recent cross-sectional observational study of 175 patients with minimum 2 years follow-up 
reported that 62% were seizure-free for at least one year, and 54% for at least two years[19]. In a 
study of 105 JME patients who had been in remission for at least 1 year, only 29% maintained 
seizure freedom after 2-3 years with the majority showing relapse strongly associated with 
provoking factors such as missed medication and sleep deprivation[20]. 
 
Rates of JAE remission previously reported 
A meta-analysis of 23 study cohorts of 2,303 patients with absence epilepsy found that 78% of 
patients with AS alone, and 35% of patients with AS and GTCS became ‘seizure free’[21]. 
Remission rates varied in studies from 21% to 89%. This meta-analysis was not specific to JAE 
and included any absence seizure syndromes. The criteria for being ‘seizure free’ also varied in 
these papers. However, there have been a small number of studies that have looked specifically 
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at JAE patients. A study of 64 patients with JAE found that 62%, on treatment, were completely 
seizure free for at least two years[22]. A retrospective study of 21 JAE patients found that 43% 
on treatment had achieved seizure freedom[23]. In a further retrospective study 8/17 (44%) 
patients with JAE were seizure free on treatment [24]. A lower rate of longer 5-year remission 
was reported in a study of 46 patients where only 7 (15%) were seizure-free, and 22 patients 
(48%) were felt to have very poor control despite AED treatment[25]. Little is reported about the 
natural course of epilepsies without treatment, but one such study followed up 15 patients who 
had refused all AED treatment, of whom 5 had absence seizures and 5 had both absence and 
GTCS; the duration of follow-up was 7-27 years and 80% of those with absence seizures alone 
were in remission, compared to 20% with both seizure types[26]. 
 
In summary, there has been a range of reported remission rates from 33-88% for JME and 21-
89% for JAE. These studies were heterogeneous in terms of methodology, patient groups and 
criteria for assessing remission.  
 
Seizure relapses in JAE and JME patients after treatment withdrawal 
A recent study specifically addressed this issue in 59 patients with IGE, who were assessed and 
diagnosed in two hospitals over 8 years[27]. Subjects were in remission on AEDs for at least 2 
years and then had at least two years follow up. 7/17 with JME and 3/11 with JAE had AEDs 
reintroduced because of a deteriorating EEG before seizures could relapse; of those remaining 
off AEDs, 10/10 with JME and 4/8 with JAE relapsed. Ninety-five percent of all relapses in the 
study were within 24 months of AED withdrawal. This contrasts with a similar study from the 
same team of 52 patients with juvenile onset cryptogenic focal epilepsies withdrawn from AEDs 
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after at least 2 years remission and followed for at least 2 years[28]. The relapse rate in these was 
only 38%, although again the vast majority (over 90%) who relapsed did so within 2 years of 
withdrawal. Three studies of 12, 4, and 130 JME patients respectively, have reported relapse 
rates of 100% after withdrawing AED treatment [14, 29, 30]. In a study of 43 JME patients, 90% 
of patients who had treatment withdrawn later relapsed[11]. Another study found that 9/11 (82%) 
JME patients who had valproate withdrawn relapsed[4]. Similar rates have been reported in two 
studies, one of 186 patients with JME in remission[13], and one of 175 JME patients overall[19], 
where for both only 9% remained seizure-free off treatment. Slightly more optimistic outcomes 
are reported in recent papers. One study found that 6 out of 9 JME patients in remission who 
stopped AED treatment remained seizure free after follow-up of 8-30 years, and in the three 
patients where seizures relapsed, reintroduction of medication gave seizure freedom again[16]. 
Of 39 seizure-free JME patients, out of a cohort of 66, 11 remained seizure free off 
treatment[18]. In 21 of 42 JME patients in remission, 7 remained so off treatment[17].  
 
Two studies of JAE patients have found that all attempts to withdraw treatment led to relapse[22, 
23]. One prospective study of AED discontinuation in childhood epilepsies found that 9 seizure 
free patients with JAE had treatment withdrawn and only 3/9 relapsed[30]. 
 
In summary, many studies report a high relapse rate for both JME and JAE patients who had 
been in remission, after AED withdrawal, but this review suggests that a significant minority do 
retain seizure freedom off treatment.  
 
Rational for and aims of this clinical audit 
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Although there is literature documenting the high relapse rate for JME on AED withdrawal, the 
literature for JAE is sparser, based on smaller numbers, and not so persuasive. We wanted to 
assess: 1) how often our patients with JAE or JME become seizure free on AEDs; 2) how often 
we withdrew AEDs; 3) how many relapsed if and when treatment was withdrawn; and 4) how 
many relapsed if they stayed on treatment beyond 2 years of remission. We wanted to gather data 
about the variance in our practice and outcomes of drug withdrawal, to inform future discussions 
with our patients. 
 
Methods 
This was a retrospective clinical chart review of young persons’ and adults’ epilepsy clinic visits, 
focusing on seizure freedom, AED withdrawal, and seizure relapse after AED withdrawal. 
Clinical practice and outcomes were compared to the literature. This clinical audit was approved 
and registered with our hospital Clinical Audit Department. 
 
Cases with JAE and JME were identified systematically and consecutively using clinic lists and 
databases from both a Young Person (Transition) Epilepsy Clinic and an Adult Epilepsy Clinic. 
The patients were all diagnosed by a consultant paediatric neurologist or adult neurologist with 
expertise in epilepsy diagnosis and management (WPW, MFO’D, SS), in accordance with the 
1989 classification[2]. It is our practice to diagnose JME in patients with features of both JME 
and JAE.  
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Data was extracted by LH and RA and entered onto Excel spreadsheets. Cases were then 
grouped into ‘two years seizure free’ or ‘not two years seizure free’, ‘treatment withdrawn’ or 
‘not withdrawn’, and ‘relapsed’ or ‘not relapsed’.  Only descriptive statistics were used. 
 
Results  
The study identified 36 patients with JAE and 145 with JME. All diagnoses were found to be in 
accordance with ILAE 1989 criteria[2].  At the time of audit, the JAE patients were aged 16-59 
years (mean 26) and JME patients were aged 13-92 years (mean 32). 27/36 (75%) of the JAE 
patients were female, as were 87/145 (60%) with JME. For the majority of patients, age of first 
seizure onset was 1-18 years (figure 1), including those with previous childhood absence 
epilepsy (CAE) and febrile seizures (FS). They had specific seizure combinations (see table 1), 
and compatible interictal or ictal EEG features, and normal or only non-specific and incidental 
abnormalities on neurological examination, or brain MRI when done: MRI or CT was only done 
in 16/36 (44%) and 68/145 (47%) cases with JAE and JME respectively.  
 
The proportions of patients who were completely seizure free of all seizure types for two years 
were 14/36 (39%) with JAE, and 32/145 (22%) with JME. After this period of remission, AED 
withdrawal was attempted in 6/14 (43%) with JAE, and in 10/32 (31%) with JME (figure 2). 
 
Juvenile Absence Epilepsy (JAE) outcomes 
For the 6/14 seizure free JAE patients who had AED withdrawal, relapse occurred in 6 (100%), 
at between 1 month and 3 years (mean 11 months): 5 had GTCS with or without AS, 1 AS alone 
(table 1). 
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In the 8/14 seizure free JAE patients who did not undergo AED withdrawal (figure 2a), relapse 
occurred in 2 (25%), at between 2 and 4 years (mean 3 years) after 2 years of seizure freedom. 
For the 6/8 patients who did not relapse, follow up time was between 1 and 6 years (mean 2 
years) after the first 2 years of seizure freedom (table 2). 
 
Juvenile Myoclonic Epilepsy (JME) outcomes 
For the 10/32 seizure free JME patients who had AED withdrawal, relapse occurred in 8/10 
(80%) at between 1 month and 15 years (mean 5 years, 11 months) of AED withdrawal, 4/8 
(50%) within 2 years of treatment withdrawal (table 2). Seven had GTCS with or without 
myoclonic seizures, 1 had myoclonic seizures alone. For the 2 patients who did not relapse, 
follow up time was at least 3 years. 
 
In the 22/32 seizure free JME patients who did not have AED withdrawal, 8/22 (36%) relapsed 
at between 2 and 12 years (mean 5 years) of being 2 years seizure free (figure 2b). For the 14 
patients who did not relapse, follow up time was between 1 year and 11 years (mean 4 years), 
after the first 2 years seizure freedom (table 2).  
 
Other outcomes 
There were some patients who did not fit the criteria of remission from all types of seizure but in 
whom treatment did control GTCS. This was true for 17/145 (12%) patients with JME. 
Furthermore, 25/145 (17%) JME patients were lost to follow up.  
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Outcomes after reinstating AEDs 
All 6 JAE patients resumed AED treatment with no re-attempted withdrawals. Two have 
returned to remission, 1 has been lost to follow up and 3 have continuing seizures. All 3 patients 
who continue to have seizures have GTCS after previously being in remission from GTCS and 
absences.  
 
All 8 JME patients were restarted on AED treatment and none had withdrawal re-attempted. Two 
returned to remission, 4 were lost to follow up, and 2 continued to have seizures after resuming 
AED treatment. Both patients who continue to have seizures have GTCS and myoclonus after 
previously being in remission from these types of seizure.  
 
Discussion  
The remission rate for JME in this study was low compared to previous studies. This may partly 
be explained by patient selection. Patients in our study were likely to be difficult cases of JME 
and JAE that had been referred to specialist clinics, rather than being managed in the community 
by General Practitioners (GPs), family physicians, and in non-specialist paediatric clinics. It is 
plausible that those lost to follow-up were more likely to be in remission and returned to 
community follow-up by their GP, than to have continuing seizures. However it is unlikely that 
all those lost to follow-up were in remission so the real remission rate is likely to be between 
22% (32/145 seizure free patients) and 39% (32/145 seizure free patients and 25/145 patients lost 
to follow up) for JME. Also, the length of follow up in this study was relatively short (up to 14 
years).  Some previous studies followed patients for up to 25 years, giving more time for 
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remission to occur [5, 10-12]. This shorter follow-up may have contributed to the low remission 
rate we observed.  
 
This study is notable, compared to the previous literature, in using patients from the same 
background population with the same clinicians and the same methods of analysis to compare 
JAE and JME patients. JAE and JME patients had similar high rates of relapse after treatment 
withdrawal (JAE 83%; JME 80%). This study is unique in comparing the relapse rates following 
withdrawal of AEDs after remission, to relapse rates in those with at least 2 years remission but 
not withdrawn (JAE 25%; JME 36%) (figure 3).  
 
Our relapse rates for JAE and JME are similar and within the ranges previously reported. In 
counselling patients however it is important to relate this risk of relapse to the risk of relapse if 
they stay on AEDs. Our data suggest that about 20% of those with JME can withdraw AEDs 
successfully after a 2 year remission on treatment. We had no successful withdrawals in patients 
with JAE, in agreement with some previous reports[22, 23]. However, our numbers were small, 
and the literature dose suggest that some patients may withdraw AEDs after 2 years remission 
without relapse[21, 27]. Some patients will want to try this. For these patients it is important to 
let them know that if they do relapse then recommencing AEDs has a reasonable chance of 
leading to remission again, but not necessarily in all.  
 
We were surprised that as many as 43% patients with JAE, and 31% of JME attending our 
epilepsy clinics attempted the withdrawal of their AEDs after 2 years of remission. Most doctors 
are wary of withdrawing drugs in JME, but many patients hope or believe they have outgrown 
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their epilepsy and express a desire to try withdrawal.  It is interesting to speculate that these 
opposing views tended to side with “patient preference” over “doctor’s orders” in our cohort, 
perhaps reflecting the increasing move towards patient-centred medicine.  Their doctors listened 
to and supported them in attempting to come off AEDs, even though the relapse rates turned out 
to be 100% for JAE (compared to 25%), and 80% (compared to 36%) for JME.  
It was also pertinent that re-introduction of AEDs did not always lead to a further remission. 
Our audit results will not only enable us to council patients more realistically in the future, but 
will be useful for patients attending other clinics, especially for those with JAE. We hope that 
future audits will show fewer patients with JAE and JME electing to try AED withdrawal. 
 
Limitations of the study 
This was not hypothesis driven clinical research, but a systematic and objective clinical audit of 
our practice concerning patients with JAE and JME reaching a 2 year remission on AEDs, and 
the decisions made about AED withdrawal and their consequences. It is an accurate description 
of what happened. However, while it may inform others’ practice, it was not designed to answer 
the questions: how many patients with JAE and JME will relapse off AEDs after a 2 year 
remission, and how easily will it be to re-establish remission by reinstating the AEDs if needs 
be? It necessarily lacked sufficient power and study design to answer these questions 
confidently.  
 
These questions could be addressed potentially, though with considerable difficulty, by a 
randomised controlled trial: similar to the Medical Research Council (MRC) study[31], but with 
syndrome diagnoses.   However, it is doubtful that a large enough number of physicians and 
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patients would be willing to randomise such choices, and we doubt the feasibility of controlling 
both placebo and nocebo effects, e.g. using a placebo controlled design. In short an observational 
study, like this clinical audit, but including a larger multicentre patient population, may be the 
only feasible way of convincingly addressing this important issue.         
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Table 1 Seizure types 
 
JAE seizure types Number 
Absence only 9 
Absence + GTC 25 
Absence + GTC + Myoclonic# 1 
Absence + Unspecified 1 
 
JME seizure types Number 
Myoclonic only 4 
Myoclonic + GTC 61 
Myoclonic + GTC + Absence 64 
Myoclonic + Absence 4 
Myoclonic + GTC + Absence + Atonic 1 
Myoclonic + Unspecified 12 
 
JAE = Juvenile Absence Epilepsy; GTC = generalised tonic-clonic; JME = Juvenile Myoclonic 
Epilepsy; #the myoclonus reported in this case was not captured on EEG, occurred very rarely, 
and was not awakening typical of JME. 
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Table 2 Important time lengths in JAE and JME patients who were seizure free for at least 
2 years  
  
  Time between EVENT A ( in 
treatment not withdrawn group 
EVENT A is 2 year seizure free 
date) and EVENT B (in did not 
relapse group event B is last 
follow up date) 
EVENT 
A 
EVENT B Mean  Range  
Seizure 
free 
JAE 
patients 
(14)  
Treatment 
withdrawn 
(6/14) 
Relapsed 
(6/6) (100%) 
11 months  1 month – 3 years  
Did not 
relapse (0/6) 
N/A 
 
N/A 
Treatment 
not 
withdrawn   
(8/14) 
Relapsed 
(2/8) (25%) 
3 years 2-4 years 
Did not 
relapse (6/8) 
(75%) 
2.2 years  <1 year – 6 years  
Seizure 
free 
JME 
patients 
(32) 
Treatment 
withdrawn 
(10/32) 
Relapsed 
(8/10) (80%) 
5.9 years  1 month – 15 years  
Did not 
relapse (2/10) 
(20%) 
> 3 years  Unknown  
Treatment 
not 
withdrawn 
(22/32) 
Relapsed 
(8/22) (36%) 
5 years  2 years to 12 years  
Did not 
relapse 
(14/22) 
(64%) 
5 years 1 month – 14 years AC
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Figure 1 Age at first seizure 
 
a) Age distribution of JAE patients at first seizure 
 
 
 
 
8/36 (22%) patients with JAE did not have the age at first seizure recorded. 
 
 
b) Age distribution of JME patients at first seizure  
 
 
 
 
59/145 (41%) with JME did not have the age at first seizure recorded 
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Figure 2 Flow diagram of patient outcomes 
a) JAE results 
 
JAE = Juvenile Absence Epilepsy; AEDs = antiepileptic drugs. 
 
b) JME results 
 
JME =Juvenile Absence Epilepsy; GTCS = generalised tonic-clonic seizures; AEDs = 
antiepileptic drugs 
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Figure 3 Relapse % observed in those withdrawn and not withdrawn from AEDs, after at 
least 2 years seizure freedom 
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